Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Express Scripts
Boehringer Ingelheim
Dow
Merck

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR HYDROCORTISONE ACETATE; UREA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Hydrocortisone Acetate; Urea

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00915343 ↗ Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency Completed Shire Phase 2/Phase 3 2007-08-21 This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency
NCT01014364 ↗ Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated Assistance Publique - Hôpitaux de Paris Phase 3 2010-03-01 The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient.
NCT01014364 ↗ Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated University of Versailles Phase 3 2010-03-01 The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient.
NCT01055249 ↗ UVB Model Validation Study Completed X-pert Med GmbH Phase 1 2010-01-01 Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.
NCT01495910 ↗ A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2011-12-01 The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
NCT01702103 ↗ Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays Unknown status PH&T S.p.A. Phase 3 2012-10-01 Demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).
NCT01771328 ↗ Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia Unknown status Haukeland University Hospital Phase 2 2013-02-01 The conventional glucocorticoid replacement therapy in congenital adrenal hyperplasia (CAH) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This method was recently applied to treat a patient through a critical phase of puberty. This is a clinical trial aiming to evaluate CSHI treatment in patients with CAH. The main objective is to determine the effects of CSHI on metabolic parameters (androstenedione and 17-hydroxyprogesterone profiles, and testosterone,adrenocorticotropic hormone(ACTH), cortisol, and bone markers), and to determine the required glucocorticoid doses. Secondary objectives are to determine effects on clinical status, body weight, blood pressure and other metabolic parameters, as well as on subjective health status (AddiQoL, SF36).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrocortisone Acetate; Urea

Condition Name

Condition Name for Hydrocortisone Acetate; Urea
Intervention Trials
Internal Hemorrhoids 2
Congenital Adrenal Hyperplasia 2
Healthy 1
Pneumonia, Viral 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrocortisone Acetate; Urea
Intervention Trials
Adrenogenital Syndrome 4
Adrenal Hyperplasia, Congenital 4
Hemorrhoids 3
Hyperplasia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrocortisone Acetate; Urea

Trials by Country

Trials by Country for Hydrocortisone Acetate; Urea
Location Trials
United States 18
Norway 2
France 1
Argentina 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrocortisone Acetate; Urea
Location Trials
Michigan 4
California 3
Texas 3
New York 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrocortisone Acetate; Urea

Clinical Trial Phase

Clinical Trial Phase for Hydrocortisone Acetate; Urea
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrocortisone Acetate; Urea
Clinical Trial Phase Trials
Completed 10
Unknown status 5
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrocortisone Acetate; Urea

Sponsor Name

Sponsor Name for Hydrocortisone Acetate; Urea
Sponsor Trials
Children's Hospital Los Angeles 2
Feinstein Institute for Medical Research 2
University of Michigan 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrocortisone Acetate; Urea
Sponsor Trials
Other 19
Industry 9
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Colorcon
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.